*By Bridgette Webb* With midterm elections fast approaching, many in [Washington](https://www.washingtonpost.com/news/powerpost/paloma/the-cybersecurity-202/2018/07/30/the-cybersecurity-202-the-fight-over-election-security-comes-to-the-senate-floor/5b5dd0ad1b326b0207955e1b/?noredirect=on&utm_term=.b1ac3187ea55) have cybersecurity on the brain. Amit Yoran, CEO of cybersecurity firm Tenable, admits it's a dangerous moment. "There are no shortage of threat actors out there, whether it's a nation-state or cybercriminal," Yoran said in an interview with Cheddar on Thursday. But, Yoran added, the solution is clear. "It doesn't matter who these actors are, the key to cybersecurity is making sure your systems are up to date. Cybersecurity is the greatest challenge of our time." It's a sentiment that both those in the capital and on Wall Street seem to share. Tenable took to the public markets on July 26 and ended the day up 30 percent. Tenable allows companies to quantify in dollars the damage that could be caused by various types of security breaches. In recent months, the company has amassed more than 24,000 customers in 160 countriesーincluding government agencies and 53 percent of Fortune 500 companies . The company raised $240 million in its IPO, which Yoran said he plans on putting to good work. "The company is going to continue investing in distribution and in our sales team to make sure we are bringing our technologies to the market." For more on this story [click here](https://cheddar.com/videos/tenable-soars-on-market-debut).

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More